$Nevro Corp. (NVRO)$
REDWOOD CITY, Calif., July 16, 2018 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO),
a global medical device company that is providing innovative, evidence-based
solutions for the treatment of chronic pain, today announced preliminary
unaudited revenue for the second quarter ended June 30, 2018.

The company announced that preliminary unaudited second quarter 2018 worldwide
revenue is expected to be approximately $96.1 million, compared to $78.0
million in the second quarter of 2017.

Preliminary unaudited U.S. revenue for the second quarter of 2018 is expected
to be approximately $79.9 million. Preliminary unaudited international revenue
for the second quarter of 2018 is expected to be approximately $16.2 million.

The company expects worldwide revenue for the full year 2018 to be in the
range of $385.0 to $390.0 million. This compares to previous expectations for
2018 worldwide revenue in the range of $400.0 to $410.0 million, as announced
in May 2018.